Brought to you by 
Eiger nets $20mm via follow-on
09 Nov 2017
Executive Summary
Eiger BioPharmaceuticals Inc. netted $20mm through the follow-on public offering of 2.1mm common shares (including full exercise of the overallotment) at $10 each. The company will use some of the funds for ongoing development of its four candidates, all of which are in Phase II--ubenimex for lymphedema and hypertension (licensed from Nippon Kayaku), exendin 9-39 for hypoglycemia, pegylated interferon lambda for hepatitis delta virus (from BMS), and Sarasar (lonafarnib) for HDV (from Merck).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eiger nets $20mm via follow-on
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice